Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

s from the September 2010 financing, was approximately $37.6 million.
  • For 2010, management anticipates total operating expenses will be $3 to $5 million less than those reported for 2009, which were approximately $72 million. Excluding the proceeds from the financing, the company continues to expect a net cash burn of $40 to $45 million for the year 2010.

  • Upcoming Corporate PresentationHalozyme representatives are scheduled to present at the following investor conference:

  • Lazard Capital Markets 7th Annual Healthcare Conference, November 17, 2010, 8:30 a.m. EST, New York City

  • To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for 90 days after the event.

    Conference CallHalozyme management will host a conference call and webcast on November 5, 2010 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and replay ID # 359750. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

    About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extra
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... September 30, 2014 Fast, ... of chemistry in documents ChemAxon ... and consulting services for life science research, launches ... generate Markush structures from documents. Markush ... property, however generating and understanding Markush structures is ...
    (Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
    (Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
    (Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 ... Core Facility Management Benchmarking study which focuses on ... the common challenges core managers face today. , In ... were revealed. One of note is the year-over-year decrease ... contributions. Core managers appear to be feeling the constraints ...
    Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
    ... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
    ... Feb. 7 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) ... Access, is scheduled to deliver a presentation about the ... on February 13, 2008 at,12:30 pm Eastern Time. The ... City at the Waldorf Astoria Hotel., The presentation ...
    ... 7 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ; ... Chief Executive Officer, is scheduled to present at,the ... Bentsur will present an,overview of the Company including ... for the treatment of diabetic neuropathic,pain. Mr. Bentsur,s ...
    Cached Biology Technology:Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2
    (Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
    (Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
    (Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
    Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2
    ... the heels of his discovery in Montana of the first ... Martin has found evidence of more dinosaur burrows this ... Australia. The find, to be published this month in ... dinosaurs of different species, in different hemispheres, and spanned millions ...
    ... BIRMINGHAM, Ala. The American Heart Association has pledged ... at Birmingham (UAB) biomedical engineering undergraduate students who are ... using hand-held remote controls from the Nintendo Wii video ... Islam and Zach Clark began work on the project ...
    ... available in German . , Infections ... often caused by bacteria called Pseudomonas aeruginosa. Once they ... virulence factors and can enter into a slimy state, ... of quorum sensing, which cells use to "sense" cell ...
    Cached Biology News:Down Under dinosaur burrow discovery provides climate change clues 2Down Under dinosaur burrow discovery provides climate change clues 3UAB students' Nintendo Wii CPR earns American Heart Association support 2A matter of density, not quantity 2
    DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
    ...
    ... deuterium atoms at the 3, 3', 4, ... use as an internal standard for the ... spectrometry. PGE1 is the theoretical cyclooxygenase metabolite ... virtually undetectable in the plasma of normal ...
    Assay Diluent Trial Pack, 4 x 100 mL...
    Biology Products: